Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC_EX:A61K39/395

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/234387IL-2/IL-15Rßy AGONIST DOSING REGIMENS FOR TREATING CANCER OR INFECTIOUS DISEASES
WO 26.11.2020
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
Appl.No PCT/EP2020/064132 Applicant CYTUNE PHARMA Inventor MOEBIUS, Ulrich
The present invention provides pulsed cyclic administration regimes and pulsed administration regimes for interleukin-2/interleukin-15 receptor βɣ (IL-2/IL-15Rβɣ) agonists for treating or managing cancer or infectious diseases in human patients. The administration regimes inter alia involve daily administration of IL-2/IL-15Rβɣ agonists on 2, 3 or 4 consecutive days followed by days without administration.
2.WO/2020/236667METHODS OF TREATING CANCER
WO 26.11.2020
Int.Class A61K 31/427
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
425Thiazoles
427not condensed and containing further heterocyclic rings
Appl.No PCT/US2020/033311 Applicant GB006, INC. Inventor DUPONT, Jakob
Disclosed herein are methods for treating cancer by administration to a patient in need thereof, an effective amount of (Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene) methyl) furan-2-yl) benzoic acid or pharmaceutically acceptable salts thereof and pembrolizumab. In some embodiments, the choline salt Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene) methyl) furan-2-yl) benzoic acid is administered. In some embodiments, the patient has a solid tumor.
3.WO/2020/236626METHODS AND SYSTEMS FOR TREATING MICROBIAL DISEASE
WO 26.11.2020
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/US2020/033210 Applicant HERZLINGER, George A. Inventor HERZLINGER, George A.
The present disclosure provides methods and systems for treating a biological fluid of a subject suffering from a microbial infection (e.g., a drug-resistant microbial infection). In some embodiments, these methods and systems involve a complement receptor immobilized on, or otherwise associated with a polymer substrate, for example, high surface area particles, membranes, hollow fibers, and/or other porous or non-porous media. In other embodiments, the methods and systems involve a complement receptor present in a dialysate used in a dialyzer for extracting pathogens out of a biological fluid, for example, the blood of a patient.
4.WO/2020/234834METHOD OF TREATING INFLAMMATORY BOWEL DISEASE WITH A COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF ALPHA
WO 26.11.2020
Int.Class A61P 1/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
04for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Appl.No PCT/IB2020/054859 Applicant JANSSEN BIOTECH, INC. Inventor GERMINARO, Matthew
A method of treating inflammatory bowel disorders, such as ulcerative colitis, comprises administering an IL-23 inhibitor, such as an anti-IL-23p19 antibody (e.g., guselkumab) and a TNF-α inhibitor, such as an anti-TNF-α antibody (e.g., golimumab).
5.WO/2020/234432ANTAGONISTS OF THE COMPLEMENT SYSTEM FOR USE IN METHODS OF TREATING PARAPROTEINEMIC NEUROPATHIES
WO 26.11.2020
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/EP2020/064234 Applicant ARGENX BVBA Inventor BLANCHETOT, Christophe
The present invention relates to a method of treating a paraproteinemic neuropathy in a subject by administering to the subject an antagonist of the complement system. The antagonist inhibits the complement system upstream of complement factor C5. More specifically, the antagonist may be an antibody or an antigen-binding fragment thereof that blocks or inhibits the complement system by inhibiting the C2b domain of complement factor C2. The paraproteinemic neuropathies that may be treated include, in particular, multifocal motor neuropathy (MMN), chronic inflammatory demyelinating polyneuropathy (CIDP), and Guillain-Barré syndrome (GBS).
6.WO/2020/234642ANTIBODIES AGAINST DISEASE CAUSING AGENTS OF POULTRY AND USES THEREOF
WO 26.11.2020
Int.Class C07K 16/20
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
20from protozoa
Appl.No PCT/IB2020/000380 Applicant NOVOBIND LIVESTOCK THERAPEUTICS INC. Inventor ABNOUSI, Hamlet
Described herein are methods and antibodies useful for reducing, eliminating, or preventing infection with a parasite population in an animal. Also described herein are antigens useful for targeting by heavy chain antibodies and VHH fragments for reducing a parasite population in an animal.
7.WO/2020/236792CD19 BINDING MOLECULES AND USES THEREOF
WO 26.11.2020
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/US2020/033559 Applicant NOVARTIS AG Inventor GRANDA, Brian
The present disclosure provides CD19 binding molecules that specifically bind to CD19, including monospecific, bispecific and trispecific binding molecules, conjugates comprising the CD19 binding molecules, and pharmaceutical compositions comprising the CD19 binding molecules and the conjugates. The disclosure further provides methods of using the C19 binding molecules to treat diseases and disorders associated with expression of CD19. The disclosure yet further provides recombinant host cells engineered to express the CD19 binding molecules and methods of producing the CD19 binding molecules by culturing the host cells under conditions in which the CD19 binding molecules are expressed.
8.WO/2020/233571BISPECIFIC MOLECULE, AND PREPARATION AND USE THEREOF
WO 26.11.2020
Int.Class C07K 16/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
Appl.No PCT/CN2020/091060 Applicant SHANGHAI YICHEN BIOMED CO.LTD Inventor WANG, Feng
Provided is a bispecific molecule, and a preparation and a use thereof. The bispecific molecule comprises a molecule that specifically binds to interleukin-1 receptor (IL-1R) and an antibody that targets radical inflammatory factors. The molecule that specifically binds to cell surface interleukin-1 receptor (IL-1R) aggregates the antibody that targets radical inflammatory factors linked thereto on or near the cell surface, thereby increasing the local concentration of the bispecific molecule on or near the cell surface, avoiding adverse reactions, increasing treatment effectiveness and also reducing the infection risk of patients.
9.WO/2020/236751CIRCULATING BIOMARKERS OF PRECLINICAL PULMONARY FIBROSIS
WO 26.11.2020
Int.Class A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
Appl.No PCT/US2020/033467 Applicant ELEVEN P15 INC. Inventor SCHWARTZ, David, A.
Disclosed herein are biomarkers related to preclinical pulmonary fibrosis and methods of identifying the same. In embodiments, the biomarkers are proteins. In embodiments, the biomarkers are transcripts.
10.WO/2020/233540STABLE SECUKINUMAB INJECTION AND PREPARATION METHOD THEREFOR
WO 26.11.2020
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/CN2020/090776 Applicant TONGHUA DONGBAO PHARMACEUTICAL CO., LTD. Inventor WANG, Depeng
Provided are a stable secukinumab injection and a preparation method therefor. The stable secukinumab injection is composed of the following ingredients: 50 mg/ml - 300 mg/ml of secukinumab, 5 mmol/L - 50 mmol/L of histidine and a histidine hydrochloride, 5 mmol/L - 50 mmol/L of methionine, 150 mmol/L - 400 mmol/L of a low-sugar alcohol, and 0.01% - 0.02% of polysorbate 80, wherein the balance is water for injection, and the pH is 5.0 - 7.0. Stability tests prove that the quality of the stable secukinumab injection is stable, wherein the stability thereof is superior to that of commercial varieties on the market, and same has various indicators that meet the relevant regulations of the Chinese Pharmacopoeia, and has good application prospects.